Definitions
Sorry, no definitions found. You may find more data at virologic.
Etymologies
Sorry, no etymologies found.
Support

Help support Wordnik (and make this page ad-free) by adopting the word Virologic.
Examples
-
Virologic success (left) was defined as reaching the limit of detection, i.e. 50 copies of HIV RNA per one ml blood.
PLoS ONE Alerts: New Articles Hendrik Weisser et al. 2010
-
Virologic response was achieved by 95% of patients with less than 100,000 copies/ml and in 77% of patients with more than 100,000 copies/ml when they were taking the three-drug combination.
MedPageToday.com - medical news plus CME for physicians 2010
-
Virologic response was seen in 80% of patients with baseline viral load of less than
MedPageToday.com - medical news plus CME for physicians 2010
-
"Virologic failure rarely resulted in resistance," he said.
MedPageToday.com - medical news plus CME for physicians 2010
-
The following points should be considered when initiating therapy with PEGINTRON in combination with REBETOL: (1) These indications are based on achieving undetectable HCV-RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose.
-
Fung SK, Chae HB, Fontana RJ, et al. Virologic response resistant mutants.
Recently Uploaded Slideshows helsim 2009
-
The following points should be considered when initiating therapy with PEGINTRON in combination with REBETOL: (1) These indications are based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose.
-
Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More.
unknown title 2011
-
Maternal Virologic, Immunologic, and Clinical Response
Elites TV 2010
-
"Pharmacogenomic Analysis Reveals Improved Virologic Response in All IL-28B G.notypes in Naive G.notype 1 Chronic HCV Patients Treated with G.-5005 Therapeutic Vaccine plus Peg-IFN/Ribavirin" will be presented by John G. McHutchison, M.D., associate director of the Duke Clinical Research Institute at Duke University Medical Center.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.